Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : MSFT Internet Explorer vs. NSCP Navigator -- Ignore unavailable to you. Want to Upgrade?

To: Keith Hankin who wrote (20767)	8/27/1998 11:08:00 PM
From: Daniel Schuh	Read Replies (1) \| Respond to of 24154

This Wendy Goldman Rohm's sure making a well timed splash, the Red Herring thing this week was the first I'd ever heard of her. Book mistimed to come out Sept. 8, they were going by the old court date apparently. On little quote I can't resist. Joachim Kempin, Microsoft's senior vice president of OEM marketing and sales, told Vobis officials that Microsoft would charge Vobis $9 per machine to carry MS-DOS only, but $18 per machine if it wanted to carry MS-DOS on the same machine with DR-DOS. These per-processor pricing tactics were subsequently made illegal by the 1995 Consent Decree Microsoft signed with the Department of Justice. ( from zdnet.com ) Oh, that's what Anne Bingaman's meaningless consent decree meant, Microsoft couldn't charge more for every machine shipped if an OEM happened to believe in "choice", in some non-Microsoftese sense. I thought it meant it couldn't force OEMs to pay for an OS for every machine shipped, silly me. Now I understand why you can't buy a PC without Windows. That business of charging OEMs more if they shipped Netscape wasn't so innovative after all, just well established standard Microsoft business practice. Bill's postmodern communist economics at its best. Think old legal pit bull Boies will have to go have a few more words with Kempin on this one? Maybe it's more a matter for the Caldera trial, also coming up soon. Cheers, Dan.